High-Throughput Plasma Proteomic Profiling Identifies Novel Biomarker Candidates in Parkinson’s Disease with Cognitive Decline
Molecular & Cellular Proteomics · 2026-11 · 101703
DOI: 10.1016/j.mcpro.2026.101703 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2026-11. Verfasst von Shervin Khosousi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Healthy Brain Ageing, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, U…. Die Arbeit nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Parkinson's disease (PD) is a common neurodegenerative disease diagnosed based on its cardinal motor features. Many PD patients experience non-motor symptoms, including cognitive decline, which can be particularly debilitating. Fluid biomarkers in PD are lacking, but modern proteomic techniques have allowed for high-throughput studies which have generated promising results. Mass spectrometry provides an unbiased approach to biomarker discovery, and the plasma proteome reflects ongoing disease processes throughout the body, including the central nervous system. Plasma samples from 198 individuals (130 PD and 68 controls) from the Swedish Biopark cohort were TMT-tagged, pre-fractionated, and analysed using untargeted mass spectrometry. Robust peptides from candidate biomarkers were technically verified using parallel reaction monitoring (PRM). The analyses focused on PD diagnosis and cognitive decline. Results were compared with plasma Neurofilament light chain levels analysed on the SIMOA platform. Several promising candidate biomarkers were discovered for PD diagnosis, cognitive decline, and motor impairment in the discovery phase. Peptides from six of the 12 proteins quantified with PRM correlated with quantifications from the discovery phase. Following PRM verification, it was found that peptides from C9 and APOC3 had altered levels in PD compared with controls. Additionally, SAA1 was found to be associated with both cognitive and motor impairment. Neurofilament light chain levels were elevated in PD with cognitive impairment but showed a weaker correlation with cognitive function than SAA1. In conclusion, untargeted mass spectrometry is a viable method for generating novel candidate biomarkers in PD plasma, several of which were technically verified with PRM including SAA1, C9, and APOC3.
Autor:innen und Institutionen
- Centre for Healthy Brain Ageing, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom; Department of Clinical Neuroscience, Karolinska Institu…
- Centre for Healthy Brain Ageing, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom.
- Centre of Excellence for Mass Spectrometry, King's College London, London, United Kingdom.
- Department of Pharmaceutical Biosciences, Spatial Mass Spectrometry, Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
- Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Basic & Clinical Neuroscience, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingd…
Zitieren
APA
Khosousi, S., Velayudhan, L., Yang, X., Lynham, S., Andrén, P. E., Hye, A., & Svenningsson, P. (2026). High-Throughput Plasma Proteomic Profiling Identifies Novel Biomarker Candidates in Parkinson’s Disease with Cognitive Decline. Molecular & Cellular Proteomics, 101703. https://doi.org/10.1016/j.mcpro.2026.101703
Vancouver
Khosousi S, Velayudhan L, Yang X, Lynham S, Andrén PE, Hye A, et al. High-Throughput Plasma Proteomic Profiling Identifies Novel Biomarker Candidates in Parkinson’s Disease with Cognitive Decline. Molecular & Cellular Proteomics. 2026:101703. doi:10.1016/j.mcpro.2026.101703
BibTeX
@article{Khosousi2026,
author = {Khosousi, Shervin and Velayudhan, Latha and Yang, Xiaoping and Lynham, Steven and Andrén, Per E and Hye, Abdul and Svenningsson, Per},
title = {High-Throughput Plasma Proteomic Profiling Identifies Novel Biomarker Candidates in Parkinson’s Disease with Cognitive Decline},
journal = {Molecular & Cellular Proteomics},
year = {2026},
pages = {101703},
doi = {10.1016/j.mcpro.2026.101703}
}
EUVIMED